The global Viscosupplementation Devices Market was valued at USD 4.08 billion in 2021, by DelveInsight

The global Viscosupplementation Devices Market was valued at USD 4.08 billion in 2021, growing at a CAGR of 7.94% during the forecast period from 2022 to 2027, to reach USD 6.43 billion by 2027. The rise in demand for Viscosupplementation Devices is primarily attributed to the rising prevalence of osteoarthritis coupled with the growing old age population, growing demand for non-surgical treatment, increasing advancements in the development of hyaluronic acid-based therapies, and well-defined reimbursement policy for viscosupplements, among others.

Viscosupplementation Devices Overview

Viscosupplementation devices are preparations that have hyaluronic acid filled in an injection, which is administered into the knee joint to relieve pain associated with osteoarthritis.

Download Sample Report- https://www.delveinsight.com/sample-request/viscosupplementation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Regions covered in the report
• Global

Recent Developmental Activities in the Viscosupplementation Devices Market:

• In August 2021, Seikagaku announced the launch of HyLink®, an Intra-Articular Single Injection Viscosupplement for the treatment of knee osteoarthritis in Taiwan.
• In January 2021, Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare commercially launched NeoVisc+ 2 mL and NeoVisc ONE 4 mL in Canada for the treatment and improvement of joint functionality and pain in patients suffering from degenerative or mechanical arthropathy of the knees.
• In May 2020, OrthogenRx announces New TriVisc® Patient Programs. In these programs the company released new pricing options relating to The TriVisc Direct Purchase Program™ and The TriVisc Patient Assistance Program™.

Key Takeaway from the Viscosupplementation Devices Market Report Study

• Market size analysis for current market size (2021), and market forecast for 5 years (2022-2027)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Viscosupplementation Devices market.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the Global Viscosupplementation Devices Market.
• Various opportunities available for the other competitor in the Viscosupplementation Devices Market space.
• What are the top-performing segments in 2021? How these segments will perform in 2027.
• Which are the top-performing regions and countries in the current market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Viscosupplementation Devices market growth in the coming future?

Viscosupplementation Devices Market Dynamics

Viscosupplementation devices are gaining momomnetum in the recent years. According to WHO, Osteoarthritis (OA) is a long-term chronic disease characterized by the deterioration of the cartilage in joints which results in bones rubbing together and creating stiffness, pain, and impaired movement. The disease most commonly affects the joints in the knees, hands, feet, and spine and is relatively common in the shoulder and hip joints.

Do you know the report market size? visit here- https://www.delveinsight.com/report-store/viscosupplementation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Viscosupplementation Devices Market Segment Analysis

• Viscosupplementation Devices Market By Product Type (Single Injection, Three Injections, and Five Injections)
• Viscosupplementation Devices Market By End-User (Hospitals, Orthopaedic Clinics, and Others)
• Viscosupplementation Devices Market By Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Viscosupplementation Devices Product Segment

The single injection is expected to emerge as a foremost segment during the forecasted period. This is because single injection viscosupplementation products are relatively newer and are also cost-effective in comparison to already existing 3-5 injection viscosupplementation products. For instance, as per the study Knee Viscosupplementation: Cost-Effectiveness Analysis between Stabilized Hyaluronic Acid in a Single Injection versus Five Injections of Standard Hyaluronic Acid published in the year 2017 by Estades-Rubio F.J. et al., a statistically significant improvement was observed for patients treated with single stabilized hyaluronic acid injection versus those who received standard hyaluronic acid in five injections. Also, the study supports the use of single injection products in the treatment of knee OA and found a slight improvement in the economic impact on the healthcare system.
North America is expected to dominate the overall Viscosupplementation Devices market
This domination is owing to the favorable reimbursement scenario, advanced healthcare infrastructure, and developed research & development facilities in the region. For instance, In the United States, Orthovisc, Supartz Hyalgan, Synvisc, and other viscosupplementation products are approved by the FDA as Class III medical devices for the treatment of knee pain caused by osteoarthritis and are reimbursed by Medicaid, Medicare and other state health care programs. Further, the rising prevalence of joint associated disorders such as arthritis and osteoarthritis among the population in the US is also anticipated to fuel the viscosupplementation market in the region. According to the Center for Disease Control and Prevention (CDC) 2018, report about 43.5% (23.7 million) of the 54.4 million adults were living with arthritis and with the aging of the US population, the prevalence of arthritis is expected to increase in the coming decades. In addition, the report also states that by the year 2040, an estimated 78.4 million (25.9% of the projected total adult population) adults aged 18 years and older will suffer from arthritis.

Viscosupplementation Devices Market Companies
Some of the key market players operating in the Viscosupplementation Devices market include Anika Therapeutics, Inc., SEIKAGAKU CORPORATION, Sanofi, Zimmer Biomet, Smith & Nephew, Ferring B.V., Lifecore Biomedical, LLC, LG Chem, Fidia Farmaceutici S.p.A, OrthogenRx, Bioventus, DePuy Synthes (Johnson & Johnson), Vivacy, APTISSEN, KiOmed Pharma, BioPolymer GmbH & Co KG, ALBOMED® GmbH and others.

Request Sample Report- https://www.delveinsight.com/sample-request/viscosupplementation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Viscosupplementation Devices Market Report Introduction
2. Viscosupplementation Devices Market Executive summary
3. Regulatory and Patent Analysis
4. Viscosupplementation Devices Market Key factors analysis
5. Viscosupplementation Devices Porter's Five Forces Analysis
6. COVID-19 Impact Analysis on Viscosupplementation Devices Market
7. Viscosupplementation Devices Market layout
8. Viscosupplementation Devices Global Company Share Analysis - Key 3-5 Companies
9. Viscosupplementation Devices Company and Product Profiles
10. Project Approach
11. KOL Views
12. DelveInsight Capabilities
13. Disclaimer
14. About DelveInsight

Do you have any query related to report? If yes, visit here- https://www.delveinsight.com/report-store/viscosupplementation-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.